Pioneering precision medicines, faster.
We are biotechnology and engineering experts, building advanced medicines from the ground up with precision and innovation.
Using proprietary technologies including programmable single-stranded DNA fabrication and AI-supported molecular design, we overcome existing development challenges to bring new therapies to market.
Our goal? To develop effective and safe advanced therapies for unmet medical needs.
A Story of Progress
At CPTx, we are pioneering single-stranded DNA technology and manufacturing processes to engineer advanced therapies faster and more reliably than ever before.
Founded in 2021 in Munich, Germany, and now also with offices in South San Francisco, California, we set out to translate more than 15 years of foundational research at the Technical University of Munich into novel therapeutics. Merging science and engineering, we leverage programmable DNA-based fabrication technologies to create novel multi-modal drugs that include targetable delivery functionalities.
Our leadership team includes high profile academic and industry experts, enabling us to address disease challenges across genetic, infectious, and autoimmune diseases fields.
15+
Years of Research10+
Nature & Science Papers Published100+
Research Papers Authored
A Team of Experts
Dr. Hendrik Dietz founded CPTx Bio in 2021 to carry forward 15 years of research and development of single stranded DNA programming and manufacturing processes. Committed to transforming theoretical ideas into practical applications, at CPTx he has assembled the talent and infrastructure needed to advance this work to solve deep challenges in the field of genetic medicines. Prior to CPTx, Dr. Dietz held faculty and research positions at Technical University of Munch (TUM) and Harvard School of Medicine, and is the recipient of numerous honors and awards, including the Gottfried Wilhelm Leibniz Prize. He received a PhD in Physics from TUM.
Dr. Grant Boldt joined as Chief Operating Officer in early 2024 and brings years of organizational and scientific leadership experience. Prior to joining the team, he was an executive in the pharmaceutical manufacturing and biotechnology sectors, including roles as Vice President (VP) of Research Pharmaceuticals at Sigma-Aldrich, Senior VP and Business Unit Head of Biologics at Lonza, and Executive VP of Biologics at Avantor. Dr. Boldt has been a frequent author and speaker throughout his career with a focus on advancing innovative scientific ideas into progress-driving applications. He received a PhD in Chemical Biology from Scripps Research Institute.
McDavid Stilwell became Chief Financial Officer in early 2025 and brings more than 25 years of experience in finance, corporate development, investor relations and communications. He was previously CFO at Coherus Biosciences during a period in which the company launched multiple new products into the U.S. market. Earlier he held senior leadership roles at Sangamo Therapeutics, Orexigen Therapeutics, and GTx, Inc. Prior to entering the biopharmaceutical industry, he was senior analyst at Shadwell Capital, a hedge fund, and he also worked several years as a journalist. His cross-functional expertise is critical to continuing to build the internal and external foundation of the company. He received a MBA from Harvard Business School.
Dr. Oschmann is a seasoned executive with extensive experience in biopharma, life science tools, and specialty chemicals. He was the Chairman and CEO at Merck KGaA, where he spearheaded the company's transformation into a leading science and technology firm. Under his leadership, Merck introduced two blockbuster products in neuroscience and oncology. Following his seven-year tenure at Merck, he became chairman of UCB and AiCuris, and he currently works as a partner at the private equity firm Armira. His earlier career included senior roles at Merck & Co. (MSD), including President of Emerging Markets and President of Europe/Middle East/Africa, after starting in R&D at MSD and working in research at the International Atomic Energy Agency. He earned a doctorate (DVM) from the University of Munich.
Pioneering in Place
Our state-of-the-art production facility in Munich is at the forefront of nanofabrication technology.
We have 3,600m2 of upstream and downstream parallel processing capacity with exceptional scalability for the footprint. Good Manufacturing Practice (GMP) validation is in process.
In-house process development & manufacturing
